Skip to main content
Premium Trial:

Request an Annual Quote

Benitec Announces Positive Animal Data with Lung Cancer Drug Candidate

Premium

Benitec Biopharma last week announced that a collaborator generated preclinical data showing that the company’s expressed RNAi technology can be used to boost survival in a orthotopic mouse model of non-small cell lung cancer.

The work, which was conducted by the Children’s Cancer Institute Australia of the University of South Wales, indicated that animals treated with Benitec’s Tribetarna, which targets the beta III tubulin gene, and chemotherapy survived “significantly” longer than those receiving chemotherapy alone.

After sixty days, 50 percent of the mice treated with Benitec’s drug were alive, versus 14 percent in the chemotherapy-only group.

Benitec said it is currently in discussions with a Ground Zero Pharmaceuticals, a US-based clinical research organization, about initiating discussions with the US Food and Drug Administration to test Tribetarna in humans.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.